$3.69 Billion is the total value of BB BIOTECH AG's 29 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 22.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | Celgene Corp. | $412,514,000 | +0.7% | 3,564,298 | +0.3% | 11.18% | -8.4% |
| INCY | Sell | Incyte Corp. | $389,788,000 | +12.1% | 3,740,406 | -1.4% | 10.57% | +2.1% |
| ISIS | Buy | Isis Pharmaceuticals Inc. | $341,238,000 | -6.5% | 5,929,426 | +3.5% | 9.25% | -14.9% |
| GILD | Sell | Gilead Sciences Inc. | $317,942,000 | +13.1% | 2,715,596 | -5.2% | 8.62% | +2.9% |
| RDUS | Buy | Radius Health Inc. | $265,529,000 | +73.3% | 3,922,140 | +5.4% | 7.20% | +57.7% |
| AGIO | Buy | Agios Pharmaceuticals Inc. | $221,160,000 | +26.8% | 1,989,921 | +7.6% | 6.00% | +15.4% |
| VRTX | Vertex Pharmaceuticals Inc. | $164,777,000 | +4.7% | 1,334,445 | 0.0% | 4.47% | -4.7% | |
| NBIX | Buy | Neurocrine Biosciences Inc. | $153,861,000 | +21.0% | 3,221,552 | +0.6% | 4.17% | +10.1% |
| MDVN | Buy | Medivation Inc. | $147,381,000 | -10.4% | 1,290,556 | +1.2% | 4.00% | -18.5% |
| ALXN | Buy | Alexion Pharmaceuticals Inc. | $140,536,000 | +20.6% | 777,428 | +15.6% | 3.81% | +9.8% |
| HALO | Sell | Halozyme Therapeutics Inc. | $137,222,000 | +49.6% | 6,077,168 | -5.4% | 3.72% | +36.2% |
| RCPT | Buy | Receptos Inc. | $126,435,000 | +20.7% | 665,272 | +4.7% | 3.43% | +9.8% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc. | $115,734,000 | +32.7% | 965,499 | +15.6% | 3.14% | +20.7% |
| REGN | Regeneron Pharmaceuticals Inc. | $101,006,000 | +13.0% | 198,000 | 0.0% | 2.74% | +2.8% | |
| NVAX | Sell | Novavax Inc. | $91,125,000 | +30.4% | 8,180,000 | -3.2% | 2.47% | +18.6% |
| TTPH | Buy | Tetraphase Pharmaceuticals Inc. | $71,497,000 | +32.1% | 1,507,114 | +2.0% | 1.94% | +20.2% |
| ALDR | New | Alder Biopharmaceuticals | $61,188,000 | – | 1,155,150 | +100.0% | 1.66% | – |
| PBYI | Puma Biotechnology Inc. | $60,942,000 | -50.6% | 521,991 | 0.0% | 1.65% | -55.0% | |
| CEMP | Buy | Cempra Inc. | $60,711,000 | +44.7% | 1,766,900 | +44.5% | 1.65% | +31.7% |
| PTCT | Buy | PTC Therapeutics Inc. | $60,303,000 | -15.9% | 1,252,912 | +6.4% | 1.64% | -23.4% |
| CLVS | Clovis Oncology Inc. | $54,326,000 | +18.4% | 618,188 | 0.0% | 1.47% | +7.8% | |
| TSRO | Buy | Tesaro Inc. | $53,180,000 | +8.4% | 904,582 | +5.9% | 1.44% | -1.3% |
| ICPT | Buy | Intercept Pharmaceuticals | $43,622,000 | -0.2% | 180,719 | +16.6% | 1.18% | -9.1% |
| INFI | Buy | Infinity Pharmaceuticals Inc. | $29,573,000 | -19.3% | 2,700,737 | +3.1% | 0.80% | -26.5% |
| JUNO | New | Juno Therapeutics, Inc. | $23,999,000 | – | 450,000 | +100.0% | 0.65% | – |
| KITE | New | Kite Pharma, Inc. | $21,340,000 | – | 350,000 | +100.0% | 0.58% | – |
| ACHN | Achillion Pharmaceuticals Inc. | $11,335,000 | -10.1% | 1,279,340 | 0.0% | 0.31% | -18.4% | |
| THRX | Sell | Theravance Inc. | $5,992,000 | -54.2% | 331,594 | -60.1% | 0.16% | -58.4% |
| TBPH | New | Theravance Biopharma Inc. | $4,677,000 | – | 359,190 | +100.0% | 0.13% | – |
| IMGN | Exit | ImmunoGen Inc. | $0 | – | -2,840,816 | -100.0% | -0.76% | – |
| GEVA | Exit | Synageva BioPharma Corp. | $0 | – | -1,025,476 | -100.0% | -2.98% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N.V. #1
- Biotech Invest N.V. #2
- Biotech Target N.V. #3
- Biotech Growth N.V. #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.